These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16918297)

  • 1. Protective effect of irradiated renal carcinoma expressing hepatitis B surface antigen against renal-cell carcinoma-mediated tumors.
    Moon Y; Cho SG; Lee JW; Min WS; Kim CC; Lee HK; Kim YG; Chang HS; Chae HS; Kim HY; Tani K
    Cancer Biother Radiopharm; 2006 Jun; 21(3):211-6. PubMed ID: 16918297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
    J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines.
    Nishisaka N; Maini A; Kinoshita Y; Yasumoto R; Kishimoto T; Jones RF; Morse P; Hillman GG; Wang CY; Haas GP
    J Immunother; 1999 Jul; 22(4):308-14. PubMed ID: 10404432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells.
    Nishitani MA; Sakai T; Ishii K; Zhang M; Nakano Y; Nitta Y; Miyazaki J; Kanayama HO; Kagawa S; Himeno K
    Cancer Gene Ther; 2002 Feb; 9(2):156-63. PubMed ID: 11857033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
    Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
    Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions.
    Xu L; Zheng J; Nguyen DH; Luong QT; Zeng G
    J Immunother; 2013 Oct; 36(8):412-22. PubMed ID: 23994888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration.
    Hara I; Nagai H; Miyake H; Yamanaka K; Hara S; Micallef MJ; Kurimoto M; Gohji K; Arakawa S; Ichihashi M; Kamidono S
    Cancer Gene Ther; 2000 Jan; 7(1):83-90. PubMed ID: 10678360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
    Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
    Suchorska WM; Dams-Kozlowska H; Kazimierczak U; Wysocki PJ; Mackiewicz A
    Expert Opin Biol Ther; 2011 Dec; 11(12):1555-67. PubMed ID: 21995459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice.
    Gotsman I; Alper R; Klein A; Rabbani E; Engelhardt D; Ilan Y
    Cancer; 2002 Jan; 94(2):406-14. PubMed ID: 11900226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of lung metastases of murine renal cell carcinoma by the combination of radiation and interferon-alpha-producing tumor cell vaccine.
    Nishisaka N; Jones RF; Morse P; Kuratsukuri K; Romanowski R; Wang CY; Haas GP
    Cytokines Cell Mol Ther; 2000 Dec; 6(4):199-206. PubMed ID: 11565958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma.
    Mendiratta SK; Quezada A; Matar M; Thull NM; Bishop JS; Nordstrom JL; Pericle F
    Hum Gene Ther; 2000 Sep; 11(13):1851-62. PubMed ID: 10986558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant hepatitis B virus surface antigen formulated with B-type CpG oligodeoxynucleotide induces therapeutic immunity against hepatitis B virus surface antigen-expressing liver cancer cells in mice.
    Zhou X; Wei H; Sun P; Wu X; Wan M; Zhang P; Guo S; Zhao T; Yu Y; Wang L
    Cancer Biother Radiopharm; 2012 May; 27(4):234-42. PubMed ID: 22537404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for murine renal cell carcinoma using genetically engineered tumor cells to secrete interleukin-12.
    Kasaoka Y; Nakamoto T; Wang J; Usui T; Hamada H
    Hiroshima J Med Sci; 2000 Mar; 49(1):29-35. PubMed ID: 10824454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
    Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
    J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.
    Wang J; Nakamoto T; Kasaoka Y; Usui T; Hamada H
    Hiroshima J Med Sci; 2000 Mar; 49(1):73-82. PubMed ID: 10824460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secreted type of modified interleukin-18 gene transduced into mouse renal cell carcinoma cells induces systemic tumor immunity.
    Hara S; Nagai H; Miyake H; Yamanaka K; Arakawa S; Ichihashi M; Kamidono S; Hara I
    J Urol; 2001 Jun; 165(6 Pt 1):2039-43. PubMed ID: 11371924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation.
    Krup OC; Kroll I; Böse G; Falkenberg FW
    J Immunother; 1999 Nov; 22(6):525-38. PubMed ID: 10570751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of antigen specific cellular immunity by vaccination with peptides from MN/CA IX in renal cell carcinoma.
    Shimizu K; Uemura H; Yoshikawa M; Yoshida K; Hirao Y; Iwashima K; Saga S; Yoshikawa K
    Oncol Rep; 2003; 10(5):1307-11. PubMed ID: 12883698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.